TRON: A Randomised, Double Blind, Placebo-controlled Study of RAD001 (Everolimus) in the Treatment of Neurocognitive Problems in Tuberous Sclerosis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2018
At a glance
- Drugs Everolimus (Primary)
- Indications Cognition disorders; Tuberous sclerosis
- Focus Therapeutic Use
- Acronyms TRON
- 29 Jan 2018 Planned End Date changed from 1 Jul 2018 to 6 Aug 2018.
- 29 Jan 2018 Planned primary completion date changed from 1 Sep 2017 to 6 Aug 2018.
- 29 Jan 2018 Status changed from recruiting to active, no longer recruiting.